Text: H.Res.576 — 106th Congress (1999-2000)All Bill Information (Except Text)

Text available as:

  • TXT
  • PDF (PDF provides a complete and accurate display of this text.) Tip?

Shown Here:
Engrossed in House (09/27/2000)

[Congressional Bills 106th Congress]
[From the U.S. Government Printing Office]
[H. Res. 576 Engrossed in House (EH)]

                 In the House of Representatives, U.S.,

                                                    September 27, 2000.
Whereas an estimated 12,400 children will be diagnosed with cancer in the year 
Whereas cancer is the leading cause of death by disease in children under age 
Whereas an estimated 2,300 children will die from cancer in the year 2000;
Whereas the incidence of cancer among children in the United States is rising by 
        about one percent each year;
Whereas 1 in every 330 Americans develops cancer before age 20;
Whereas approximately 8 percent of deaths of those between 1 and 19 years old 
        are caused by cancer;
Whereas a number of opportunities for childhood cancer research remain unfunded 
        or underfunded;
Whereas limited resources for childhood cancer research hinder the recruitment 
        of investigators and physicians to pediatric oncology;
Whereas peer-reviewed clinical trials are the standard of care for pediatrics 
        and have improved cancer survival rates among children; and
Whereas a recent study indicates that, based on parental reports, 89 percent of 
        children with cancer experienced substantial suffering in the last month 
        of life: Now, therefore, be it
    Resolved, That it is the sense of the House of Representatives that Congress 
should support--
            (1) public and private sector efforts to promote awareness about the 
        incidence of cancer among children, the signs and symptoms of cancer in 
        children, and treatment options;
            (2) increased public and private investment in childhood cancer 
        research to improve prevention, diagnosis, treatment, and long-term 
            (3) policies that provide incentives to encourage medical trainees 
        and investigators to enter the field of pediatric oncology;
            (4) policies that provide incentives to encourage the development of 
        drugs and biologics designed to treat pediatric cancers;
            (5) policies that encourage participation in clinical trials; and
            (6) medical education curricula designed to improve pain management 
        for cancer patients.